NasdaqGS:SANABiotechs
Is Sana Biotechnology (SANA) Ready to Balance FDA Scrutiny With Its Cash-Intensive Gene Therapy Vision?
Sana Biotechnology recently faced an analyst downgrade amid growing concerns about a tighter U.S. FDA regulatory framework for gene therapies, putting a spotlight on its cash usage and clinical progress ahead of its mid-March 2026 quarterly update.
This combination of shifting regulation and divergent analyst opinions has intensified questions about how the company will balance scientific ambition with financial resilience.
We’ll now examine how the analyst downgrade against a more stringent...